C
아이진
185490KOSDAQ52.0 / 100
Reference Date: 2026-10-23
Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 3.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Ajin is a biotech venture company focused on R&D in medicine and pharmacy, specializing in the development of next-generation innovative therapies such as mRNA-based vaccines and AAV gene therapies. The company is also advancing revenue-generating projects, including meningococcal vaccines and botulinum toxin development, while investing in promising ventures to secure key technologies.
Number of Employees
49people
Average Salary
58.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.48Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
-36.31Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
7.00Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲6.8% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲38.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -30.8% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (56%)
Current 1,859Won52-week high 2,37552-week low 1,193
1-month return2.0Point
1m -3.63% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral[기재정정]반기보고서 (2026.06)2026-09-29